JPMorgan Chase & Co. decreased its holdings in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 63.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,800 shares of the biopharmaceutical company’s stock after selling 107,000 shares during the period. JPMorgan Chase & Co. owned 0.24% of Esperion Therapeutics worth $3,087,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in Esperion Therapeutics by 69,371.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 4,856 shares during the last quarter. SG Americas Securities LLC raised its position in Esperion Therapeutics by 74.5% during the 2nd quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 2,991 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Esperion Therapeutics by 12.7% during the 2nd quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after acquiring an additional 806 shares during the period. State of Wisconsin Investment Board purchased a new position in shares of Esperion Therapeutics during the 2nd quarter worth approximately $509,000. Finally, American International Group Inc. grew its holdings in shares of Esperion Therapeutics by 21.6% during the 3rd quarter. American International Group Inc. now owns 11,257 shares of the biopharmaceutical company’s stock worth $564,000 after acquiring an additional 2,001 shares during the period. 92.24% of the stock is owned by institutional investors and hedge funds.
Shares of Esperion Therapeutics Inc (NASDAQ ESPR) opened at $66.98 on Friday. The firm has a market capitalization of $1,720.00, a P/E ratio of -9.76 and a beta of 2.73. Esperion Therapeutics Inc has a 52 week low of $10.71 and a 52 week high of $68.60.
A number of research analysts have weighed in on ESPR shares. Northland Securities reiterated a “buy” rating and set a $72.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Chardan Capital reiterated a “neutral” rating and set a $75.00 target price (up previously from $20.00) on shares of Esperion Therapeutics in a report on Tuesday, December 5th. Cowen started coverage on Esperion Therapeutics in a report on Thursday, September 7th. They set an “outperform” rating and a $64.00 target price on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Finally, Needham & Company LLC upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their target price for the stock from $72.00 to $81.00 in a report on Thursday, December 14th. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $60.85.
In related news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total value of $502,205.10. Following the sale, the director now owns 2,472 shares in the company, valued at approximately $133,117.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 32.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/01/05/esperion-therapeutics-inc-espr-holdings-reduced-by-jpmorgan-chase-co.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.